Lyra Therapeutics, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
OTC.Pink
Lyra Therapeutics has filed an S-1 registration statement to allow selling securityholders to resell up to 846,744 shares of common stock, following a recent private placement and the announcement of mixed Phase 3 clinical trial results for its lead product candidate, LYR-210.